{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:12:09Z","timestamp":1790892729831,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Training Fellow","award":["NIHR303264"],"award-info":[{"award-number":["NIHR303264"]}]},{"name":"NIHR Advanced Fellowship","award":["NIHR302258"],"award-info":[{"award-number":["NIHR302258"]}]},{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","award":["RE18933\/BSTOP5"],"award-info":[{"award-number":["RE18933\/BSTOP5"]}],"id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. \u2018As needed\u2019 biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this mixed-methods study was to gain insight into the perspectives of both patients and clinicians regarding the acceptability of an \u2018as needed\u2019 approach to biologic therapy in psoriasis, including potential barriers and enablers to implementation in routine care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We first conducted UK-wide online scoping surveys of patients with psoriasis and dermatology clinicians to explore their views on \u2018as needed\u2019 biologic therapy. Using topic guides informed by these survey findings, we then carried out qualitative focus groups with patients and clinicians. Themes were identified using reflexive thematic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 67 patients and 27 clinicians completing the scoping surveys, 67% (43 of 64 patients) and 78% (21 of 27 clinicians) supported the use of \u2018as needed\u2019 biologic therapy, respectively. Respondents highlighted advantages such as a reduction in healthcare burden and greater ownership of care. Challenges included logistics of \u2018as needed\u2019 drug provision and potential risks of disease flare and drug immunogenicity. Focus groups comprised 15 patients with psoriasis [9 female patients (60%), average disease duration 32 years (range 9\u201364)] and 9 dermatology clinicians [8 female clinicians (89%), average dermatology experience 20 years (range 8\u201333)]. Both patients and clinicians felt that an \u2018as needed\u2019 treatment approach will deliver a reduction in treatment burden and present an opportunity for patient-led ownership of care. Both groups highlighted the importance of ensuring ongoing access to medication and discussing the potential impact of psoriasis recurrence. Patient preferences were influenced by their lived experiences, particularly previous difficulties with medication delivery logistics and establishing disease control. Clinician perspectives were informed by personal experience of their patients adapting their own dosing schedules. Clinicians highlighted the importance of targeted patient selection for an \u2018as needed\u2019 approach, ongoing disease monitoring, and prompt reaccess to medications upon psoriasis recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data indicate that \u2018as needed\u2019 biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost-effectiveness is warranted to enable the real-world potential of this approach to be realized.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae068","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T14:31:09Z","timestamp":1708180269000},"page":"243-251","source":"Crossref","is-referenced-by-count":6,"title":["Acceptability of \u2018as needed\u2019 biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study"],"prefix":"10.1093","volume":"191","author":[{"given":"David","family":"Gleeson","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneeha","family":"Naveed","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Moorhead","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McAteer","sequence":"additional","affiliation":[{"name":"Psoriasis Association, Northampton , Northamptonshire , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Sewell","sequence":"additional","affiliation":[{"name":"Psoriasis Association, Northampton , Northamptonshire , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"McGuire","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Weinman","sequence":"additional","affiliation":[{"name":"Centre for Adherence Research and Education, Faculty of Life Sciences & Medicine, King\u2019s\u00a0College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N W N","family":"Barker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah\u00a0C E","family":"Chapman","sequence":"additional","affiliation":[{"name":"Centre for Adherence Research and Education, Faculty of Life Sciences & Medicine, King\u2019s\u00a0College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satveer K","family":"Mahil","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"key":"2024071611291843000_ljae068-B1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"2024071611291843000_ljae068-B2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PPA.S70834","article-title":"Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective","volume":"9","author":"Bolge","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2024071611291843000_ljae068-B3","author":"National Institute for Health and Care Excellence"},{"key":"2024071611291843000_ljae068-B4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"2024071611291843000_ljae068-B5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/09546634.2020.1832649","article-title":"Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey","volume":"33","author":"Schots","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024071611291843000_ljae068-B6","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1136\/annrheumdis-2015-208317","article-title":"Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study","volume":"75","author":"Kievit","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024071611291843000_ljae068-B7","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"key":"2024071611291843000_ljae068-B8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00403-023-02566-w","article-title":"Patients\u2019 perspectives towards biologic dose reduction in psoriasis: a qualitative study","volume":"315","author":"van der Schoot","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2024071611291843000_ljae068-B9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"2024071611291843000_ljae068-B10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024071611291843000_ljae068-B11","doi-asserted-by":"crossref","first-page":"e834\u201341","DOI":"10.3399\/BJGP.2022.0137","article-title":"Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK: results from two matched case\u2013control studies","volume":"72","author":"Abo-Tabik","year":"2022","journal-title":"Br J Gen Pract"},{"key":"2024071611291843000_ljae068-B12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bjd.15307","article-title":"An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis","volume":"177","author":"Simpson","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024071611291843000_ljae068-B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","article-title":"Clinical goals and barriers to effective psoriasis care","volume":"9","author":"Strober","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024071611291843000_ljae068-B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis \u2013 insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024071611291843000_ljae068-B15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/bjd\/ljac144","article-title":"Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-\u00adsectional survey","volume":"188","author":"Quirke-McFarlane","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024071611291843000_ljae068-B16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/msc.1404","article-title":"Tapering biologic therapy for people with rheumatoid arthritis in remission: a review of patient perspectives and associated clinical evidence","volume":"17","author":"Stamp","year":"2019","journal-title":"Musculoskeletal Care"},{"key":"2024071611291843000_ljae068-B17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40271-019-00403-9","article-title":"Tapering biologic therapy for rheumatoid arthritis: a qualitative study of patient perspectives","volume":"13","author":"Chan","year":"2020","journal-title":"Patient"},{"key":"2024071611291843000_ljae068-B18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/msc.1367","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients\u2019 perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Musculoskeletal Care"},{"key":"2024071611291843000_ljae068-B19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/bjd\/ljac024","article-title":"Biologic tapering for\u00a0patients\u00a0with psoriasis with low disease activity: data from\u00a0the\u00a0French PsoBioTeq Registry","volume":"188","author":"Aubert","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024071611291843000_ljae068-B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024071611291843000_ljae068-B21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s13063-021-05681-z","article-title":"Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study \u2013 the BeNeBio study","volume":"22","author":"van der Schoot","year":"2021","journal-title":"Trials"},{"key":"2024071611291843000_ljae068-B22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide","volume":"314","author":"van Muijen","year":"2022","journal-title":"Arch Dermatol Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae068\/57399669\/ljae068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/2\/243\/58554312\/ljae068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/2\/243\/58554312\/ljae068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:30:20Z","timestamp":1721129420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/2\/243\/7609806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,17]]},"published-print":{"date-parts":[[2024,7,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae068","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,2,17]]}}}